Risk factors for the development of chemotherapy-induced neuropathy include older age, prior exposure to neurotoxins, diabetes, folate/B12 deficiencies, inter-individual variations in CYP2C8*3 [137], class IIa β-tubulin [138], FDG4, FZD3, EPHA5 [139], and the WNT pathway, among others [140]. This evidence concerns the gene EPHA5 and diabetes mellitus.